Gossamer bio announces appointment of steven d. nathan, m.d.

San diego--(business wire)--gossamer bio, inc. (nasdaq: goss), a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (pah) and pulmonary hypertension associated with interstitial lung disease (ph-ild), today announced the appointment of steven d. nathan, m.d., and skye drynan to its board of directors. dr. nathan is medical director of inova's advanced lung disease program and lung transpla.
GOSS Ratings Summary
GOSS Quant Ranking